Value of Genetic Testing for the Prediction of Long-Term Outcome in Patients With Hypertrophic Cardiomyopathy

American Journal of Cardiology

Volumn 118, Issue 6, 2016, Pages 881-887

  van Velzen, Hannah G ^a   Vriesendorp, Pieter A ^a   Oldenburg, Rogier A ^a   van Slegtenhorst, Marjon A ^a   van der Velden, Jolanda ^b,c   Schinkel, Arend F L ^a   Michels, Michelle ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; COHORT ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE; HEART FAILURE; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MYBPC3 GENE; MYH7 GENE; MYL2 GENE; NEXT GENERATION SEQUENCING; NONSUSTAINED VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SUDDEN CARDIAC DEATH; TNNT2 GENE; AGED; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

CARDIAC MYOSIN; CARRIER PROTEIN; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 3, HUMAN; MYOSIN-BINDING PROTEIN C;

ADULT; AGED; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CAUSE OF DEATH; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; GENETIC TESTING; GENOTYPE; HEART FAILURE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOSIN HEAVY CHAINS; MYOSIN LIGHT CHAINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 84995421831     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.06.038     Document Type: Article

References (25)

1. 1 Maron, B.J., Ommen, S.R., Semsarian, C., Spirito, P., Olivotto, I., Maron, M.S., Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64 (2014), 83–99.
2. 2 Lopes, L.R., Rahman, M.S., Elliott, P.M., A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart 99 (2013), 1800–1811.
3. 3 Ho, C.Y., Charron, P., Richard, P., Girolami, F., Van Spaendonck-Zwarts, K.Y., Pinto, Y., Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res 105 (2015), 397–408.
4. 4 Authors/Task Force members, Elliott, P.M., Anastasakis, A., Borger, M.A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A.A., Lafont, A., Limongelli, G., Mahrholdt, H., McKenna, W.J., Mogensen, J., Nihoyannopoulos, P., Nistri, S., Pieper, P.G., Pieske, B., Rapezzi, C., Rutten, F.H., Tillmanns, C., Watkins, H., 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 (2014), 2733–2779.
5. 5 Fujita, T., Fujino, N., Anan, R., Tei, C., Kubo, T., Doi, Y., Kinugawa, S., Tsutsui, H., Kobayashi, S., Yano, M., Asakura, M., Kitakaze, M., Komuro, I., Konno, T., Hayashi, K., Kawashiri, M.A., Ino, H., Yamagishi, M., Sarcomere gene mutations are associated with increased cardiovascular events in left ventricular hypertrophy: results from multicenter registration in Japan. JACC Heart Fail 1 (2013), 459–466.
6. 6 Lopes, L.R., Syrris, P., Guttmann, O.P., O'Mahony, C., Tang, H.C., Dalageorgou, C., Jenkins, S., Hubank, M., Monserrat, L., McKenna, W.J., Plagnol, V., Elliott, P.M., Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart 101 (2015), 294–301.
7. 7 Li, Q., Gruner, C., Chan, R.H., Care, M., Siminovitch, K., Williams, L., Woo, A., Rakowski, H., Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circ Cardiovasc Genet 7 (2014), 416–422.
8. 8 Olivotto, I., Girolami, F., Ackerman, M.J., Nistri, S., Bos, J.M., Zachara, E., Ommen, S.R., Theis, J.L., Vaubel, R.A., Re, F., Armentano, C., Poggesi, C., Torricelli, F., Cecchi, F., Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 83 (2008), 630–638.
9. 9 Plon, S.E., Eccles, D.M., Easton, D., Foulkes, W.D., Genuardi, M., Greenblatt, M.S., Hogervorst, F.B., Hoogerbrugge, N., Spurdle, A.B., Tavtigian, S.V., IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29 (2008), 1282–1291.
10. 10 Christiaans, I., Nannenberg, E.A., Dooijes, D., Jongbloed, R.J., Michels, M., Postema, P.G., Majoor-Krakauer, D., van den Wijngaard, A., Mannens, M.M., van Tintelen, J.P., van Langen, I.M., Wilde, A.A., Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J 18 (2010), 248–254.
11. 11 Alders, M., Jongbloed, R., Deelen, W., van den Wijngaard, A., Doevendans, P., Ten Cate, F., Regitz-Zagrosek, V., Vosberg, H.P., van Langen, I., Wilde, A., Dooijes, D., Mannens, M., The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J 24 (2003), 1848–1853.
12. 12 Maron, B.J., McKenna, W.J., Danielson, G.K., Kappenberger, L.J., Kuhn, H.J., Seidman, C.E., Shah, P.M., Spencer, W.H. 3rd, Spirito, P., Ten Cate, F.J., Wigle, E.D., Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines. J Am Coll Cardiol 42 (2003), 1687–1713.
13. 13 American College of Cardiology Foundation/American Heart Association Task Force on Practice; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., Naidu, S.S., Nishimura, R.A., Ommen, S.R., Rakowski, H., Seidman, C.E., Towbin, J.A., Udelson, J.E., Yancy, C.W., 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Thorac Cardiovasc Surg 142 (2011), e153–e203.
14. 14 van Dijk, S.J., Dooijes, D., dos Remedios, C., Michels, M., Lamers, J.M., Winegrad, S., Schlossarek, S., Carrier, L., ten Cate, F.J., Stienen, G.J., van der Velden, J., Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119 (2009), 1473–1483.
15. 15 van Dijk, S.J., Bezold, K.L., Harris, S.P., Earning stripes: myosin binding protein-C interactions with actin. Pflugers Arch 466 (2014), 445–450.
16. 16 Witjas-Paalberends, E.R., Piroddi, N., Stam, K., van Dijk, S.J., Oliviera, V.S., Ferrara, C., Scellini, B., Hazebroek, M., ten Cate, F.J., van Slegtenhorst, M., dos Remedios, C., Niessen, H.W., Tesi, C., Stienen, G.J., Heymans, S., Michels, M., Poggesi, C., van der Velden, J., Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res 99 (2013), 432–441.
17. 17 Tardiff, J.C., Carrier, L., Bers, D.M., Poggesi, C., Ferrantini, C., Coppini, R., Maier, L.S., Ashrafian, H., Huke, S., van der Velden, J., Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res 105 (2015), 457–470.
18. 18 Ho, C.Y., Lopez, B., Coelho-Filho, O.R., Lakdawala, N.K., Cirino, A.L., Jarolim, P., Kwong, R., Gonzalez, A., Colan, S.D., Seidman, J.G., Diez, J., Seidman, C.E., Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363 (2010), 552–563.
19. 19 Chan, R.H., Maron, B.J., Olivotto, I., Pencina, M.J., Assenza, G.E., Haas, T., Lesser, J.R., Gruner, C., Crean, A.M., Rakowski, H., Udelson, J.E., Rowin, E., Lombardi, M., Cecchi, F., Tomberli, B., Spirito, P., Formisano, F., Biagini, E., Rapezzi, C., De Cecco, C.N., Autore, C., Cook, E.F., Hong, S.N., Gibson, C.M., Manning, W.J., Appelbaum, E., Maron, M.S., Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130 (2014), 484–495.
20. 20 Ismail, T.F., Jabbour, A., Gulati, A., Mallorie, A., Raza, S., Cowling, T.E., Das, B., Khwaja, J., Alpendurada, F.D., Wage, R., Roughton, M., McKenna, W.J., Moon, J.C., Varnava, A., Shakespeare, C., Cowie, M.R., Cook, S.A., Elliott, P., O'Hanlon, R., Pennell, D.J., Prasad, S.K., Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 100 (2014), 1851–1858.
21. 21 O'Hanlon, R., Grasso, A., Roughton, M., Moon, J.C., Clark, S., Wage, R., Webb, J., Kulkarni, M., Dawson, D., Sulaibeekh, L., Chandrasekaran, B., Bucciarelli-Ducci, C., Pasquale, F., Cowie, M.R., McKenna, W.J., Sheppard, M.N., Elliott, P.M., Pennell, D.J., Prasad, S.K., Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56 (2010), 867–874.
22. 22 Vriesendorp, P.A., Liebregts, M., Steggerda, R.C., Schinkel, A.F., Willems, R., Ten Cate, F.J., van Cleemput, J., Ten Berg, J.M., Michels, M., Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2 (2014), 630–636.
23. 23 Mogensen, J., van Tintelen, J.P., Fokstuen, S., Elliott, P., van Langen, I.M., Meder, B., Richard, P., Syrris, P., Caforio, A.L., Adler, Y., Anastasakis, A., Gimeno, J.R., Klingel, K., Linhart, A., Imazio, M., Pinto, Y., Newbery, R., Schmidtke, J., Charron, P., The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J 36 (2015), 1367–1370.
24. 24 Alfares, A.A., Kelly, M.A., McDermott, G., Funke, B.H., Lebo, M.S., Baxter, S.B., Shen, J., McLaughlin, H.M., Clark, E.H., Babb, L.J., Cox, S.W., DePalma, S.R., Ho, C.Y., Seidman, J.G., Seidman, C.E., Rehm, H.L., Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 17 (2015), 880–888.
25. 25 Olivotto, I., Cecchi, F., Poggesi, C., Yacoub, M.H., Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 5 (2012), 535–546.